Good VA means good stereopsis in children

Article

Postoperative visual acuity (VA) is the factor with the most significant impact on stereopsis in paediatric unilateral pseudophakic subjects, according to study results published online ahead of print by the British Journal of Ophthalmology.

Postoperative visual acuity (VA) is the factor with the most significant impact on stereopsis in paediatric unilateral pseudophakic subjects, according to study results published online ahead of print by the British Journal of Ophthalmology.

Seung-Hyun Kim of Korea University College of Medicine, Republic of Korea and David A. Plager of Indiana University Medical Center, United States conducted a retrospective chart review of paediatric subjects undergoing unilateral cataract extraction and primary IOL implantation (n=38). Subjects were split into two groups: Group 1 subjects (n=21; stereopsis >400 seconds of arc) had a mean age of 4.9 years at presentation and 6.3 at surgery; Group 2 subjects (n=17; stereopsis <400 seconds of arc) had a mean age of 2.7 years at presentation and 3.0 at surgery. Dr Kim and Dr Plager collected data on refractive error, anisometropia, bilateral best corrected visual acuity and stereoacuity to evaluate which factors most influence stereopsis.

The data collected showed that 66.7% of Group 1 subjects and 47.1% of Group 2 subjects had no strabismus either before or after surgery. VA of 20/40 or better was achieved by 52.0% of Group 1 subjects and 5.9% of Group 2 subjects. Following multivariate regression analysis, the researchers found that subjects were significantly less likely to have good stereopsis if the VA of the pseudophakic eye was 20/60 or worse.

The researchers concluded that the factors most likely to lead to good stereopsis include later manifestation of cataract, no strabismus and achievement of good postoperative VA (≥20/40), the last of these being the most significant factor.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.